Form 4: Lyell Immunopharma CSO Reports Equity Transactions

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, reported the acquisition of 8,000 shares from vested performance-based restricted stock units and the sale of 1,453 shares for tax withholding.

Summary

• Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc. (LYEL), reported changes in his beneficial ownership.
• On August 20, 2025, Mr. Lee acquired 8,000 shares of common stock at a price of $0.
• This acquisition resulted from the vesting of performance-based restricted stock units (RSUs) granted on February 9, 2024, with 4,000 shares issued upon achievement of performance criteria and another 4,000 shares scheduled for issuance on August 20, 2026, subject to continued service.
• Following this acquisition, Mr. Lee's direct beneficial ownership increased to 16,957 shares.
• On August 21, 2025, Mr. Lee disposed of 1,453 shares of common stock at a weighted average price of $10.544 per share.
• This disposition was an automatic sale to cover tax withholding obligations arising from the settlement of vested restricted stock units.
• The sale price for these shares ranged from $10.49 to $10.64 per share.
• After these transactions, Mr. Lee's direct beneficial ownership stands at 15,504 shares.

Sentiment

Score: 7

Explanation: The filing reports routine insider transactions related to equity compensation. The acquisition of shares through performance-based vesting is a positive sign of achieved internal milestones and management alignment, while the sale for tax withholding is a standard, neutral event. No significant negative or positive operational news is conveyed.

Positives

• Chief Scientific Officer Gary K. Lee acquired 8,000 shares of common stock through the vesting of performance-based restricted stock units, indicating the achievement of internal performance criteria.
• The acquisition of shares at a $0 price reflects compensation through equity awards, which aligns management's interests with shareholders' long-term value creation.

Negatives

• The sale of 1,453 shares, while for tax withholding purposes, reduces the officer's direct beneficial ownership in the company.

Future Outlook

The filing indicates a future issuance of 4,000 shares on August 20, 2026, contingent on the reporting person's continued service, suggesting ongoing equity incentives for key management.

Industry Context

Form 4 filings are standard disclosures for insider transactions. The vesting of performance-based restricted stock units and subsequent sale for tax purposes are common occurrences in the biotechnology and pharmaceutical industries, where equity compensation is a significant component of executive remuneration. This aligns with typical practices for retaining and incentivizing key scientific leadership in growth-oriented companies like Lyell Immunopharma.

Comparison to Industry Standards

• The structure of equity compensation, involving performance-based restricted stock units and automatic sales for tax withholding, is a common practice across the biotech and broader technology sectors.
• Companies such as Moderna (MRNA) or BioNTech (BNTX) frequently utilize similar equity incentive plans to align executive interests with long-term shareholder value.
• The reported transactions are consistent with standard executive compensation and tax management practices for vested equity.

Stakeholder Impact

• Shareholders: The increase in beneficial ownership through RSU vesting aligns the Chief Scientific Officer's interests with long-term shareholder value, while the tax-related sale is a minor, routine dilution event.
• Employees: The equity compensation structure demonstrates the company's approach to incentivizing key personnel, potentially impacting employee morale and retention strategies.

Next Steps

• An additional 4,000 shares are scheduled to be issued to Gary K. Lee on August 20, 2026, subject to his continued service to Lyell Immunopharma.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation and tax obligations. It does not contain information that would fundamentally alter the investment thesis for Lyell Immunopharma. The vesting of performance-based RSUs is a positive indicator of internal goal achievement and management alignment, but the overall impact on the company's valuation or strategic direction is minimal. Therefore, a 'hold' recommendation is appropriate as there's no new material information to warrant a change in existing positions based solely on this filing.

Keywords

Lyell Immunopharma, LYEL, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Equity Compensation, Chief Scientific Officer, Gary K. Lee